|
|
|
Akebia Therapeutics http://www.akebia.com/
Akebia Therapeutics is an ischemia and vascular biology company spun-out of Procter & Gamble and co-founded by Sigvion Capital. The company’s focus is on clinical development of programs for anemia and ischemia related disorders.
Co-Investors: Thomas Weisel Partners, Kearny Venture Partners, Novartis Ventures, Triathlon Medical Ventures
Logical Therapeutics http://www.logicaltherapeutics.com/
Logical Therapeutics, a Boston based company, is developing drugs to treat a variety of medical conditions that are caused by or are associated with excessive inflammation, including various forms of arthritis, obesity and type 2 diabetes mellitus. The Company's lead compound, LT-NS001, is a pro-drug, which is converted in the bloodstream into naproxen, a non-steroidal anti-inflammatory drug (NSAID). Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class. In pre- clinical studies in rats and dogs, LT-NS001 was shown to cause significantly less damage to the gastrointestinal tract than equivalent doses of naproxen. LT-NS001 has completed pre-clinical toxicology testing and was evaluated in a Phase 1 clinical trial and shown to be well tolerated. The company plans to enter Phase 2 clinical testing in 2008.
Co-Investors: SV Life Sciences, Burrill & Company, Novo A/S
Nymirum, Inc http://nymirum.com/
Nymirum is a drug discovery company with a proprietary platform that targets RNA with small molecules.
Drug developers around the world have focused on RNA as one of the most promising new areas of the 21st century. Utilizing small molecules avoids the drug delivery difficulties inherent in nucleic acid-based siRNA and antisense approaches and enables orally available treatments for a broad range of diseases.
Accord Biomaterials http://accordbiomaterials.com/
Accord Biomaterials develops nitric oxide generating coatings for blood-contacting medical devices. Their coatings address serious complications related to clotting and altered healing, improving performance and reducing total costs of critical medical device interventions.
Co-Investors: Arboretum Ventures
Kereos, Inc http://www.kereos.com/
Kereos develops targeted therapeutics and molecular imaging agents that detect and attack cancer and cardiovascular disease earlier and more specifically than previously possible. Because Kereos' targeted therapeutics seek out definitive disease biomarkers and carry powerful payloads of proven chemotherapeutics, their specificity and potency make them potentially more effective and less toxic in treating disease. Similarly, the specificity and capabilities of Kereos molecular imaging agents enable earlier and more definitive diagnosis of disease.
Co-Investors: Genentech, Phillips Medical, Triathlon Medical Ventures, Rivervest Venture Partners, Prolog Ventures
ProNAi Therapeutics http://www.pronai.com/
ProNAi Therapeutics is an emerging biopharmaceutical company that has developed an IND approved anti cancer drug candidate with nucleic acids as the basis for the therapy.
Co-Investors: Apjohn Ventures
|
|
|
|
|
|
|
|
| |
 |
Sigvion Capital | 806 W. Washington St. | Suite 204 | Chicago, IL 60607
Phone: 312.226.6373 | Fax: 312.226.6343 | Email: sigvion@sigvion.com |
| | |
|
|
|
|
|
|
|